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Abstract
Background: With the explosion of data comes a proportional opportunity to identify novel knowledge with the
potential for application in targeted therapies. In spite of this huge amounts of data, the solutions to treating complex
disease is elusive. One reason being that these diseases are driven by a network of genes that need to be targeted in
order to understand and treat them effectively. Part of the solution lies in mining and integrating information from
various disciplines. Here we propose a machine learning method to mining through publicly available literature on
RNA interference with the goal of identifying genes essential for cell survival.
Results: A total of 32,164 RNA interference abstracts were identified from 10.5 million pubmed abstracts (2001 - 2015).
These abstracts spanned over 1467 cancer cell lines and 4373 genes representing a total of 25,891 cell gene associations.
Among the 1467 cell lines 88% of them had at least 1 or up to 25 genes studied in a given cell line. Among the 4373
genes 96% of them were studied in at least 1 or up to 25 different cell lines.
Conclusions: Identifying genes that are crucial for cell survival can be a critical piece of information especially in treating
complex diseases, such as cancer. The efficacy of a therapeutic intervention is multifactorial in nature and in many cases
the source of therapeutic disruption could be from an unsuspected source. Machine learning algorithms helps to narrow
down the search and provides information about essential genes in different cancer types. It also provides the building
blocks to generate a network of interconnected genes and processes. The information thus gained can be used to
generate hypothesis which can be experimentally validated to improve our understanding of what triggers and maintains
the growth of cancerous cells.
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Background
There is no lack for data or scientific literature as they
continue to grow at an exceedingly exponential rate; yet
there is this unquenchable thirst for knowledge. The
knowledge that can lead to new discoveries, aid in mak-
ing clinical decisions and designing efficient therapeutic
strategies are hidden within this huge mass of data and
literature. It has been shown decades earlier that the
medical literature holds hidden knowledge that can be
exploited in treating complex diseases [1–6]. In spite of
the availability of this huge amounts of literature two
thirds of the questions that clinicians raise about patient
care in their practice remain unanswered [7]. These
question most often could be classified into a small set
of generic questions [8] but require a diverse set of
answers based on the clinicians specialty. With the ad-
vances in technology and the completion of the human
genome we have data, but the challenge lies in how to
identify the crucial knowledge that can lead to a better
understanding of the disease pathology and equip the
clinician to make informed decisions as to the best
course of therapeutic action. In addition the various
factors that can influence or contribute to disease sus-
ceptibility or progression poses a challenge to scientist
in finding a preventative or therapeutic solution for
these diseases [9–11]. The challenges in finding a cure
are proportionally increasing with complexity presented
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by the disease. The question most commonly asked when
dealing with huge amounts of data is, how the low value
data can be transformed to high value knowledge which
can then be applied to treating complex diseases more ef-
fectively. There is no lack for data, but connecting the in-
formation across diverse disciplines is challenging [12–14].
The heterogeneous nature of the scientific literature
across multiple disciplines is something that can be
exploited to identify crucial knowledge that underlies the
essence of survival. The free availability of this unstruc-
tured text makes it the biggest and most widely used for
the identification of new knowledge. It would be highly
impossible for a human to devour this huge amount of lit-
erature to identify the dots that connect various compo-
nents within a pathway that can be targeted to effectively
treat a disease, especially when the information is present
in non-interacting articles. Manual curation is a possibility
with the advantage of being accurate, but comes at a high
cost of time, labor and finding expertise in multiple disci-
plines. The use of computers and more specifically ma-
chine learning algorithms that can be trained to identify
relevant literature and then extract the relationships be-
tween entities of interest to produce clinically applicable
knowledge is gaining popularity in the race to find cures.
The later though highly scalable with the ever increasing
growth of literature is error prone due to the complexity
of natural languages used. The ultimate goal of informa-
tion access is to help the user or practitioner in finding
relevant documents that satisfy their information needs so
they can gain wisdom and apply it to their practice. The
challenge still remains; how can we effectively use the
tools and resources in finding wisdom from the huge
amounts data.
RNA interference is a very powerful biological process
that involves the silencing of gene expression in
eukaryotic cells [15–20]. It is indeed a natural host
defense mechanism by which exogenous genes, such as
viruses are degraded [21–23]. With the emergence of
the RNA interference technology, scientist have been
able to study the consequences of depleting the expres-
sion of specific genes that code for pathological proteins
and are able to observe the resultant cellular phenotypes,
which can provide insights into the significance of the
gene. Diseases that are associated or driven by genes,
such as cancer, autoimmune disease and viral disease
can take advantage of RNA interference to generate a
new class of therapeutics. Synthetic RNAi can be devel-
oped to trigger the RNA interference machinery to pro-
duce the desired silencing of genes [24–26]. The power
of this process can be harnessed to identify and validated
drug targets and also in the development of targeted
gene specific medicine.
One of the benefits of RNA interference technology, is
that it provides information about the function of genes
within an organism and helps us in identifying essential
genes. Essential genes are those that are very important
towards the survival of a cell or organism [27]. Identifi-
cation of the minimum essential genes required for a cell
to survive and being able to generate distinct sets that
can represent normal versus cancer cell survival will not
only enhance our understanding on what causes a nor-
mal cell to progress into a cancerous cell but will also
provide the precise location of the gene that is the
driving force of uncontrolled cell proliferation. This cru-
cial knowledge can guide in the development of targeted
cancer treatments. For example, it is very evident today,
that breast cancer is no longer a single disease but
heterogeneous in nature requiring different prognosis
and treatments [28–31]. Since tumors are highly hetero-
geneous in nature, there may be more than one gene
that needs to be targeted within the heterogeneous
population of cells, which makes the treatment of cancer
so complex. By identifying these essential genes, one can
use them as building blocks to capture the heterogeneity
of the tumor environment and improve the clinical
decision making in treating them more effectively and
with precision.
In our study, through the use of text mining and ma-
chine learning algorithms, we were able to scan through
10.5 M abstract and retrieve those relevant to RNAi
studies. We were able to identify the genes that are es-
sential for cell survival. Given the heterogeneous nature
of complex disease, our study reveals the power of
mining literature that can be harnessed to generate hy-
pothesis leading to novel targeted clinical applications.
Methods
Abstract selection and corpus construction
The Medline database was queried for abstracts that stud-
ied the effects of siRNA or drugs on cell lines using the
following boolean query structure [(siRNA or shRNA or
drug) AND (cell line name)] across 6 different cell lines,
namely MCF7, MCF10A, SKBR3, HS578T, BT20, and
MDAMB231 The resultant PMIDs of the query were con-
verted to XML and parsed to extract the PMID, article
title and article abstract. These files formed the initial un-
filtered set of abstracts and were converted to a pdf format
to aid in the manual process of scanning them to select
the most relevant abstracts to construct the text corpus.
In addition these abstracts were further divided among
four other individuals consisting of a high school student
and three master’s level students for manual scanning and
classification. The abstracts were read and then grouped
under four categories as follows:
i. RNAi: These abstracts had siRNA/shRNA being
studied, along with the cell line used and the
resultant cell phenotype.
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ii. Drug: These abstracts had a drug being studied,
along with the cell line used and the resultant cell
phenotype.
iii. Drug-Drug: These abstracts had a drug interaction
being studied, along with the cell line used and the
resultant cell phenotype.
iv. NA (Not Applicable): If the abstract did not fall into
any of the above categories it was labelled as NA.
For an abstract to be placed in any of the categories (i) –
(iii) they needed to have all three components, namely
siRNA or drug and cell line and resultant cell phenotype. If
one of these components were not clearly stated or was
missing, the abstract was placed in the NA category. Close
to 2000 abstracts were manually screened using the above
criteria.
Training and testing datasets
The abstracts from the above classification were
converted to individual text files and used to create the
positive and negative classes namely RNAi and Non_-
RNAi. The training and testing datasets consisted of
various combinations as shown in the Table 1. The text
files representing the training and testing datasets were
converted into the WEKA native file format, namely
ARFF (attribute relation file format) using the java Text-
DirectoryLoader class. The final training set consisted of
120 RNAi abstracts in the RNAi class and a total of
1700 abstracts from drug, drug-drug, NA and RNS in
the Non_RNAi class. The testing set consisted of 101
RNAi abstracts in the RNAi class and a total of 1700 ab-
stracts from drug, drug-drug, NA and RNS in the Non_-
RNAi class.
Selection of algorithm
Evaluation is key to identifying the best classifier that
can perform the given task with the highest accuracy.
With the limited amount of data for training and testing,
the 10 fold stratified cross validation was chosen as the
most appropriate method for evaluating the various clas-
sifiers. The dataset was evaluated using the following 7
classifiers, namely, ZeroR, NaiveBayes, K-nearest neigh-
bor, J48, Random Forest, Support Vector Machine and
OneR. These are some of the most commonly used
algorithms for text classification, except for ZeroR which
was used here to get a baseline. The filtered classifier be-
longing to the WEKA [32] meta classifier was used,
since it has the advantage of simultaneous selection of a
classifier and filter to evaluate the model. The various
classifiers mentioned above were tested along with the
string to word vector filter. The string to word filter
converts string attributes into a set of attributes that
represent the word occurrences from the text contained
within the strings. The set of attributes is determined
from the training data set. The 10 fold stratified cross
validation option was selected and the data from the
training set (Table 1) was evaluated to identify the best
classifier.
Training and testing the model
Based on the classification accuracy of the above 5
models, the top three were selected for training and test-
ing These models were trained and then tested on the
dataset shown in Table 1. The highest performing model
namely SMO trained on Set 4 (SMO-4) was chosen as
the model to be used on the unknown dataset. The
model was further improved by adding a randomly gen-
erated set, to improve the classification of abstracts. A
random number generating script was used to randomly
select 10,000 numbers between 10,000,000 and
25,000,000. The numbers thus obtained were used as
PMIDs to download the respective abstracts. These
abstracts were processed and converted to the attribute
relationship file format. The 10,000 abstracts were tested
using the SMO-4 model. The abstracts that were classi-
fied as RNAi by SMO-4 were eliminated. The remaining
abstracts formed the random negative dataset. This step
ensures that the random negative set is free of positive
RNAi instances. The randomly generated dataset was in-
cluded in the dataset 5. The dataset shown in Table 1
was used to evaluate a new model using the filtered
classifier (SMO/StringToWordVector) and named as
SMO-5. The performance of SMO seemed to be better
and consistent and was chosen as the model of choice
for further analysis.
Generation of the screening dataset
The abstracts for the years 1975 – 2015 was downloaded
from the MEDLINE database. The abstracts were down-
loaded and converted to individual text files retaining
just the PMID, title and abstract text. The text files were
grouped by year and then converted to the attribute re-
lationship file format using the WEKA TextDirectory-
Loader class. The individual .arff weka input files were
updated to reflect the classes that were used to generate
Table 1 Composition of the training and testing sets used to
test the various weka classifiers
Set Training Testing Data
Positive Negative Positive Negative
1 100 300 100 300 r,d,dd,g
2 100 100 100 100 r,d,dd,na
3 100 300 100 300 r,d,dd,na
4 100 400 100 400 r,d,dd,na,g
5 120 1700 101 1700 r,d,dd,na,rns
[r: RNAi abstracts, d: drug only abstract, dd: drug interaction abstracts, na: not
applicable, rns: random negative set]
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the classification model (SMO-5), namely RNAi and
Non_RNAi.
Extraction of RNAi relevant abstracts
The weka arff files containing the abstracts for each year
from 2001 to 2015 was classified using the SMO-5
classification model on the Bigred2, a Cray XE6/XK7
supercomputer with a hybrid architecture comprising of
1020 computing nodes. A total of 10.5 million abstracts
were processed to be classified as RNAi or Non_RNAi.
The resultant file containing the PMID’s along with the
classification as RNAi or Non_RNAi was further proc-
essed to extract the PMIDs of abstracts classified as
RNAi. The abstracts for these PMID’s were retrieved
and converted to XML format retaining the PMID, art-
icle title and abstract text.
Creation of dictionary for entity recognition
A perl module was created to house the dictionaries for
gene names and cell line names. The list of gene names
along with their aliases was downloaded from HGNC
(HUGO Gene Nomenclature Committee) [33] and the
list of cell lines names along with their aliases was down-
loaded from cellosaurus [34]. These list were further
processed to form the final dictionary with cell line
names and gene names normalized to their official
names/symbols. These dictionaries are very comprehen-
sive with the Gene dictionary containing 161,863 entries
and the cell line dictionary containing 73,370 entries.
Entity tagging and cell-gene information extraction
The abstracts that were classified as RNAi were further
processed and the gene and cell line mentions were
tagged with the normalized name of the cell line or gene
name using the dictionary that was created as mentioned
above. Once tagged the abstracts were further processed
to extract the cell line name and gene names. These
were stored in a table format to preserve the genes stud-
ied in a given cell line within a given abstract.
Validation of the essential genes
The extracted genes were ranked in descending order of
number of studies associated. The genes that were stud-
ied on an average of 100 or more times were extracted
and the cell lines in which these genes were studied on
average of 20 or more times were extracted as well. In
addition the top 20 most studied genes, the median 20
genes and the bottom 20 genes were extracted. The
correctness of the extracted cell gene associations was
verified by selecting the relevant PMIDs and manually
scanning for the presence of the cell and gene informa-
tion that was extracted. The top genes predicted to be
essential for cell survival was queried against the
network of cancer genes [35] to identify their relevance
to cancer and were also queried against the Therapeutics
Target Database [36] to identify if they were drug tar-
gets. The genes were also queried against the DPSC
database [37] at a threshold p-value of <0.05 to check
for them being reported as essential genes.
Results
Identification of siRNA relevant abstracts and corpus
creation
From the approximately 2000 abstracts that were manu-
ally screened 221 belonged to the RNAi class and 1644
belonged to the Non_RNAi class. The Non_RNAi class
included abstracts from drug, drug-drug or the not
applicable class as described in the methods section. The
average inter classification agreement among individuals
who manually read the abstracts was 0.75.
Since these abstracts were initially downloaded based
on the specific cell lines prior to the manual scan, there
were duplicate abstracts among the cell lines. Following
the manual classification task, the entire dataset was
scanned for duplicate PMIDs and they were removed. In
order to get a better representative negative set, the ran-
domly generated dataset as mentioned in the methods
section which consisted of 10,000 abstracts was created.
Thus creating a dataset that had a wider coverage than
just the ones that were picked during the initial screen-
ing. The above mentioned datasets formed the text
corpus to be used for RNAi text classification. This data-
set was further divided into training and testing data for
evaluating and training the models for RNAi text
classification.
Evaluation of the classifiers
In order to get an estimate of the generalization error
each of the classifiers chosen was evaluated using the 10
fold stratified cross validation. The classifiers were evalu-
ated and the results as percent correctly classified are as
shown in Table 2. The zeroR classifier is used here to
determine the baseline performance and as a benchmark
for the other classification methods used. The zeroR
classifier is the simplest classification method and does
Table 2 The % accuracy of classification after evaluating each
classifier on a given dataset using 10 fold stratified cross validation
Classifiers Set 1 Set 2 Set 3 Set 4 Set 5
ZeroR 75.00 50.00 75.00 80.00 93.41
NaiveBayes 93.00 89.00 93.25 92.40 95.00
KNN 77.00 74.00 81.00 83.20 94.23
J48 95.00 95.00 94.50 96.60 98.46
RandomForest 91.00 95.00 84.75 82.80 93.41
SMO 94.25 94.50 94.50 96.00 98.35
OneR 88.75 78.00 88.75 91.00 96.09
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not have any predictability power. It simply builds a
frequency table of the given data and selects the most
frequent value as its prediction. It can be noted from the
Table 2 for zeroR that the percentage accurately pre-
dicted is the same as the percentage of the class that is
most abundantly present. From Table 2, it can be
observed that the composition and balance between the
positive and negative set does affect the accuracy results
of some of the classifiers. Overall the J48, NaiveBayes
and SMO seemed to be consistent across the various
datasets and more immune to the varying changes
between the dataset size and composition.
Evaluating the performance of the top 3 models
The top 3 classifier models with the highest accuracy of
prediction for a given dataset was chosen for further
analysis to determine the final model to be selected for
RNAi text classification. Each of the top 3 performing
models evaluated on a given dataset was further trained
on the respective datasets that were used for their evalu-
ation in the 10 fold stratified cross validation, following
which they were tested on a previously unseen dataset,
namely the test dataset. The performance results from
training and testing are as shown in Table 3.
In addition to the performance measures such as
percent correctly classified, precision and recall, using the
error rate is a good way of measuring the classifiers per-
formance. It can been seen from Table 4 that J48 and
SMO have the best performance according to the five
error metrics. They have the lowest values for the mean
absolute error, root mean squared error, relative absolute
error and root relative squared error and the highest value
for the kappa statistic making them the models of choice.
It can be noted that J48 and SMO performed the best.
Since SMO was consistently better across the various
datasets and SVM being a preferred, faster performing
and reliable classifier for text classification, it was chosen
for further analysis. The various performance metrics for
abstracts classified as RNAi are shown in detail for the
classifiers tested on dataset 5 in Table 5 and the classifier
errors are shown in Table 4. The J48 and SMO models
performed the best with the SMO model being faster in
time taken to build the model. In addition the ROC
curve (Fig. 1) for the SMO-5 proves its efficiency as a
very good classification model.
Genes essential for cancer cell survival
A total of 10.5 million abstracts from the years 2001 to
2015 were tested using the SMO_5 model which resulted
in 32,164 abstracts being classified as RNAi (Table 6).
These abstracts spanned over 1467 cancer cell lines and
4373 genes. There was a total of 25,891 cell gene associa-
tions identified (Table 7), out of which 97% of the associa-
tions between a cell line and a gene occurred 5 or less
times. Only 2 gene-cell line pairs were studied more than
90 times. Among the 1467 cell lines 88% of them had at
least 1 or up to 25 genes studied in a given cell line (Table
8). Among the 4373 genes 96% of them were studied in at
least 1 or up to 25 different cell lines (Table 9).
The top 10 cell lines extracted namely, MCF7, MDA-
MB-231, HELA, A549, HEPG2, HCT116, LNCAP,
HEK293, SGC7901 and SW480 (Fig. 2) had on an
average 300 or more associated gene studies and repre-
sented Breast, Lung, Colon, Gastric, Liver, Cervical,
Prostate and Kidney cancers, which are some of the
most common cancers that affect men and women. On
analyzing the cell lines and genes extracted from these
abstracts, the top 20 genes, namely AKT1, TP53, CDH1,
CCND1, VEGFA, BCL2, EGF, CDKN1A, EPHB2, BIRC5,
MYC, EGFR, SNAI1, VIM, BAX, IFI27, AHSA1, SRC,
JUN and STAT3 had on an average 100 studies or more
associated across different cell lines as shown in Fig. 3.
Among the top 20 genes, 9 of them are known cancer
genes that have a role in cellular function as shown in
Table 10 [35]. These functions are defined in the bio-
logical process branch of the Gene Ontology (GO) levels
5 and 6. Out of the top 20 genes queried against the
DPSC database, 15 of the genes were found to be es-
sential among the four cancer types, namely breast,
colon, ovarian and pancreas. In addition 11 out of the
20 genes have active drugs that are being studied in
clinical trials or being researched as a potential thera-
peutic target, some of which have been approved.
(Additional file 1: Table S1) [36].
Table 3 The % accurately classified by the top three models after training and testing
Set 1 Train Test Set 2 Train Test Set 3 Train Test
J48 99.50 94.50 J48 99.00 93.00 J48 99.50 94.50
SMO 100.00 96.25 RandomForest 100.00 97.50 SMO 100.00 94.50
NaiveBayes 98.00 86.50 SMO 100.00 93.00 NaiveBayes 98.50 84.25
Set 4 Train Test Set 5 Train Test
J48 99.00 92.40 J48 99.50 99.20
SMO 100.00 93.00 SMO 100.00 98.50
NaiveBayes 94.20 89.00 oneR 96.60 97.10
These models were previously evaluated using the 10 fold cross validation
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The top 20 genes studied on an average 20 or more
times in a given cell line was extracted and the cell lines
were associated to their respective cancer types. The
number of genes among the top 20 genes that are
associated with a given cancer type is shown in the
Additional file 1: Table S2. All of the top 20 genes were
studied in breast cancer, indicating the complexity of
this disease and the network of genes that may play a
role in the progression of this cancer.
Validation of genes predicted to be essential
The top 20 genes, the median 20 genes and bottom 20
genes were extracted and were manually verified from
the respective abstracts for their essentiality in cell
survival. The top 20 genes were all found to be essential
towards cell survival. Among the median 20 there were
around four that were false positives and among the
bottom 20 there were two that were false positives and
four that were genes found to be essential in a non-
human species (Additional file 1: Table S3).
Discussion
In multicellular organisms, cell death is a critical process
by which the damaged cells or those that pose a threat
to the organism are destroyed through a tightly regu-
lated process of cell destruction [38–40]. This process is
very essential for the overall health and survival of the
organism as it gets rid of the cells that may interfere
with its normal function [41]. It is clear that a crucial
balance between cell proliferation and cell death should
be maintained and tipping to one side could lead to a
diseased state. Cancer, the uncontrolled proliferation of
cells is one of the most complex and challenging disease
to treat as it involves many underlying molecular mecha-
nisms and moreover these mechanisms are shared alike
by cancerous as well as normal cells. This sharing makes
it difficult to therapeutically target cancerous cells
without damaging the normal cells. Most of the chemo-
therapeutic agents available today are relatively nonspe-
cific and cause considerable damage to the surrounding
normal cells, leading to severe adverse events. Thus
identifying those molecular mechanisms that are essen-
tial only to the survival of cancerous cells but not
normal cells holds the key to effective cancer treatments.
In addition the heterogeneity of cancer calls for a
systematic identification of genes that are essential for
the growth of these diverse set of cells and the resultant
cancer phenotype which can aid in the identification of
potential drug targets.
Our top hit, AKT is a major signaling hub for various
downstream substrates and is known to be critical for
cell growth and survival [42–44]. It is involved in the
progression of many human cancers [45–47]. There are
various therapeutic interventions that are currently be-
ing targeted towards the inhibition of AKT [48–50].
Perifosine, MK-2206, RX-0201, PBI-05204 and
GSK2141795 are some of the potential AKT inhibitors
being investigated in several cancers [50].The role of
AKT in promoting cell proliferation and survival in
hormone responsive MCF-7 breast cancer cells has been
previously studied [51]. The investigational drug, MK-
2206 has been found to be effective in treating breast
cancer [52]. It has been shown that increased levels of
AKT in certain cell lines is associated with acquired
resistance to antiestrogenic therapy and an inhibition of
AKT led to a pronounced growth inhibition of the cell
lines [53]. With a wide array of involvement in cell
survival and cancer progression, AKT is a potential drug
target in cancer therapy, yet finding an optimal way to
inhibit AKT has been elusive. Identifying the genes
that are essential for cell survival and those that drive
tumor resistance are critical pieces of information for
developing targeted therapies to prevent the progres-
sion of cancer.
p53 has been widely studied and is best known for its
tumor suppressing ability through the initiation of
Table 4 Classifier errors for the classifier’s tested on dataset 5
Classifier Error ZeroR NaiveBayes KNN J48 RandomForest SMO OneR
Kappa statistic 0.00 0.66 0.23 0.87 0.00 0.86 0.57
Mean absolute error 0.12 0.05 0.06 0.02 0.09 0.02 0.04
Root mean squared error 0.25 0.22 0.24 0.12 0.20 0.13 0.20
Relative absolute error 100% 40.55% 47.10% 15.63% 73.11% 13.33% 31.55%
Root relative squared error 100% 90.13% 96.73% 48.74% 79.35% 51.73% 79.59%
Table 5 Performance metrics across the various classifiers tested
on dataset 5 for abstracts classified as RNAi
Classifiers Time (sec) TPR FPR Precision Recall F-Measure
ZeroR 2.45 0.00 0.00 0.00 0.00 0.00
NaiveBayes 28.82 0.83 0.04 0.59 0.83 0.69
KNN 3.22 0.14 0.00 0.90 0.14 0.25
J48 116.14 0.83 0.00 0.93 0.83 0.88
RandomForest 70.66 0.00 0.00 0.00 0.00 0.00
SMO 6.46 0.82 0.01 0.93 0.82 0.87
OneR 12.94 0.42 0.00 0.98 0.42 0.59
[Time in seconds to build the model, True Positive Rate (TPR), False Positive
Rate (FPR)]
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apoptosis. The p53 gene once hailed as a potential thera-
peutic target to halt cancer is met with complexity as
many of its functions remain unclear. It’s ability to regu-
late the same cellular processes both positively and
negatively makes it hard to predict the outcomes of its
activation [54].
Moreover, the median 20 and bottom 20 genes, though
not frequently studied may hold the answers to treating
cancers that respond poorly to therapy. For example the
NFAT gene from our bottom 20 gene list has been found
to be involved in many solid tumors and malignancies
[55–57]. This and many other genes extracted during
this process can be exploited for their role in cancer.
Most of the top essential genes identified and
extracted through the large scale scanning of PubMed
abstracts are involved in the survival pathways and in
various malignancies – AKT1 [48–50, 53, 58–62], TP53
[54, 63, 64], CDH1 [65, 66], CCND1 [67], VEGFA [68, 69],
Fig. 1 AUC Receiver Operator Characteristics for the SMO-5 model
Table 6 The number of abstracts that were processed per year
and the number of abstracts that were identified as relevant to
RNA interference studies
Year Medline RNAi
2001 424,042 101
2002 435,427 180
2003 472,745 425
2004 514,910 745
2005 575,403 1101
2006 620,688 1503
2007 652,232 1724
2008 701,623 1996
2009 742,510 2308
2010 801,061 2707
2011 862,838 3070
2012 931,619 3923
2013 978,796 4048
2014 1,018,012 4498
2015 796,876 3835
Total 10,528,782 32,164
Table 7 The number of times a given gene and cell line were
studied together
No. of Cell Gene Associations Frequency
5 25,198
10 461
15 99
20 52
25 25
30 15
35 8
40 4
45 10
50 1
55 1
60 6
65 5
70 1
75 2
80 0
85 1
90 2
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BCL2 [70, 71], ITK [72], CDKN1A [73], EPHB2 [74, 75],
BIRC5 [76], MYC [77], EGFR [78, 79], VIM [80, 81], BAX
[82], AHSA1 [83], and SRC [84]. This suggests that the
growth and survival of cancer cells is sustained by a net-
work of genes that come into harmony to fuel the cancer
progression. This clearly brings out the importance in not
only targeting essential genes, but also those that may be
closely involved but not very evident as to their role in
fueling cancer. This calls for an extensive mining of data
and literature in search of genes that are less known but
critical in cellular processes, as these could play a crucial
role in the progression of complex disease just as rare
SNPs do. The co expression of a gene may not mean that
it is or has an influence on the essential gene identified
here. But it could mean that in the absence of the targeted
essential gene, the co-expressed gene could possible play a
role in promoting cell survival, a fact that cannot be ruled
out. The complexity of effectively treating cancers unfolds
as the network of genes linked to essential genes grow.
Identifying the potential interaction that exists between
these genes and their individual roles in cell survival or
the extent of their influence within a pathway can shed
light into developing targeted therapies that destroy
cancerous cells but leave the normal cells intact.
There are a few limitations to the method used here.
Even though majority of the genes found to be essential
are identified and associated with their respective cancer
cell lines, there have been instances where a gene or
gene alias was the same as that of a commonly used
word in English and got tagged incorrectly leading to a
false positive. Another limitation of this process is that it
cannot identify instances where a gene was specifically
found to be not essential for a given cell line.
Conclusion
It is very evident thus far that the efficacy of a thera-
peutic intervention is multifactorial in nature and in
many cases the source of therapeutic disruption could
be from an unsuspected source. This approach in
scanning millions of abstracts to identify top genes that
are essential for survival is a feat that is not possible by
Table 8 Frequency of the number of genes studied in a given
cell line
Genes Frequency
25 1291
50 73
100 54
200 30
300 10
400 3
500 1
600 2
700 0
800 1
900 1
1000 0
1100 1
Table 9 Frequency of the number of cell lines used to study a
given gene
Cell Lines Frequency
25 4209
50 96
100 46
150 10
200 5
250 3
300 1
Fig. 2 Top 10 most studied cell lines
Fig. 3 The top 20 genes predicted to be essential for cell survival
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an individual researcher or a group, just because of the
sheer volume of literature that needs to be processed and
the connections between entities to be made. Using
machine learning algorithms, has not only helped narrow
down the search and provided information about essential
genes in different cancer types but also provided the build-
ing blocks to generate a network of interconnected genes
and processes, which can be used to generate hypothesis
that can be experimentally validated to improve our
understanding of what triggers and maintains the growth
of cancerous cells. This comprehensive list of genes that
are predicted to be essential in various cancer types can be
used as an informational tool by researchers who wish to
identify more genes that may be crucial to answer the
questions they may have in treating a specific type of
cancer. Moreover when the top essential genes do not
provide all the answers that a research is seeking, they can
expand their targeted gene list by utilize this resource to
look up the less frequently studied genes which might
prove to be more critical just as rare variants are in finding
answers to treating complex diseases. Since genes that are
essential are typically involved in biological processes that
are critical to a cell, the identification of essential genes in
other species through this process can be used as a
method of identifying novel targets that would have
otherwise gone unnoticed.
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